These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

189 related articles for article (PubMed ID: 20124009)

  • 41. TNF potentiates anticancer activity of bortezomib (Velcade) through reduced expression of proteasome subunits and dysregulation of unfolded protein response.
    Nowis D; McConnell EJ; Dierlam L; Palamarchuk A; Lass A; Wójcik C
    Int J Cancer; 2007 Jul; 121(2):431-41. PubMed ID: 17373661
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Bortezomib-induced painful peripheral neuropathy: an electrophysiological, behavioral, morphological and mechanistic study in the mouse.
    Carozzi VA; Renn CL; Bardini M; Fazio G; Chiorazzi A; Meregalli C; Oggioni N; Shanks K; Quartu M; Serra MP; Sala B; Cavaletti G; Dorsey SG
    PLoS One; 2013; 8(9):e72995. PubMed ID: 24069168
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Proteasome inhibitor bortezomib promotes a rupture-prone plaque phenotype in ApoE-deficient mice.
    Van Herck JL; De Meyer GR; Martinet W; Bult H; Vrints CJ; Herman AG
    Basic Res Cardiol; 2010 Jan; 105(1):39-50. PubMed ID: 19693627
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The effect of the proteasome inhibitor bortezomib on acute myeloid leukemia cells and drug resistance associated with the CD34+ immature phenotype.
    Colado E; Alvarez-Fernández S; Maiso P; Martín-Sánchez J; Vidriales MB; Garayoa M; Ocio EM; Montero JC; Pandiella A; San Miguel JF
    Haematologica; 2008 Jan; 93(1):57-66. PubMed ID: 18166786
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The ubiquitin-proteasome system regulates the stability of neuronal nicotinic acetylcholine receptors.
    Rezvani K; Teng Y; De Biasi M
    J Mol Neurosci; 2010 Jan; 40(1-2):177-84. PubMed ID: 19693707
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Altering protein turnover in tumor cells: new opportunities for anti-cancer therapies.
    Demarchi F; Brancolini C
    Drug Resist Updat; 2005 Dec; 8(6):359-68. PubMed ID: 16406769
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Therapeutic landscape of carfilzomib and other modulators of the ubiquitin-proteasome pathway.
    Mitsiades CS
    J Clin Oncol; 2015 Mar; 33(7):782-5. PubMed ID: 25605842
    [No Abstract]   [Full Text] [Related]  

  • 48. Anti-inflammatory effect of the proteasome inhibitor bortezomib on endotoxin-induced uveitis in rats.
    Chen FT; Liu YC; Yang CM; Yang CH
    Invest Ophthalmol Vis Sci; 2012 Jun; 53(7):3682-94. PubMed ID: 22538426
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Phase I trial of the proteasome inhibitor bortezomib in patients with advanced solid tumors with observations in androgen-independent prostate cancer.
    Papandreou CN; Daliani DD; Nix D; Yang H; Madden T; Wang X; Pien CS; Millikan RE; Tu SM; Pagliaro L; Kim J; Adams J; Elliott P; Esseltine D; Petrusich A; Dieringer P; Perez C; Logothetis CJ
    J Clin Oncol; 2004 Jun; 22(11):2108-21. PubMed ID: 15169797
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Inhibition of the ubiquitin-proteasome system by natural products for cancer therapy.
    Tsukamoto S; Yokosawa H
    Planta Med; 2010 Aug; 76(11):1064-74. PubMed ID: 20186654
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sustained reduction of alloantibody secreting plasma cells and donor specific antibody with proteasome inhibition in mice.
    Redfield RR; Lou Y; Rodriguez E; Rostami S; Parsons RF; Noorchashm H; Naji A; Abt PL
    Transpl Immunol; 2013 Dec; 29(1-4):11-6. PubMed ID: 24103731
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Ubiquitin proteasome system stress underlies synergistic killing of ovarian cancer cells by bortezomib and a novel HDAC6 inhibitor.
    Bazzaro M; Lin Z; Santillan A; Lee MK; Wang MC; Chan KC; Bristow RE; Mazitschek R; Bradner J; Roden RB
    Clin Cancer Res; 2008 Nov; 14(22):7340-7. PubMed ID: 19010849
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Attenuation of early atherogenesis in low-density lipoprotein receptor-deficient mice by proteasome inhibition.
    Wilck N; Fechner M; Dreger H; Hewing B; Arias A; Meiners S; Baumann G; Stangl V; Stangl K; Ludwig A
    Arterioscler Thromb Vasc Biol; 2012 Jun; 32(6):1418-26. PubMed ID: 22516063
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Critical role of Ca
    Tomita S; Sekiguchi F; Deguchi T; Miyazaki T; Ikeda Y; Tsubota M; Yoshida S; Nguyen HD; Okada T; Toyooka N; Kawabata A
    Toxicology; 2019 Feb; 413():33-39. PubMed ID: 30552955
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Reactive nucleolar and Cajal body responses to proteasome inhibition in sensory ganglion neurons.
    Palanca A; Casafont I; Berciano MT; Lafarga M
    Biochim Biophys Acta; 2014 Jun; 1842(6):848-59. PubMed ID: 24269586
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Discovery and development of second-generation proteasome inhibitors.
    Kirk CJ
    Semin Hematol; 2012 Jul; 49(3):207-14. PubMed ID: 22726543
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Probing the specificity and activity profiles of the proteasome inhibitors bortezomib and delanzomib.
    Berkers CR; Leestemaker Y; Schuurman KG; Ruggeri B; Jones-Bolin S; Williams M; Ovaa H
    Mol Pharm; 2012 May; 9(5):1126-35. PubMed ID: 22432738
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.
    Sutheesophon K; Kobayashi Y; Takatoku MA; Ozawa K; Kano Y; Ishii H; Furukawa Y
    Acta Haematol; 2006; 115(1-2):78-90. PubMed ID: 16424655
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells.
    Nawrocki ST; Carew JS; Pino MS; Highshaw RA; Andtbacka RH; Dunner K; Pal A; Bornmann WG; Chiao PJ; Huang P; Xiong H; Abbruzzese JL; McConkey DJ
    Cancer Res; 2006 Apr; 66(7):3773-81. PubMed ID: 16585204
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Proteasome inhibition induces glutathione synthesis and protects cells from oxidative stress: relevance to Parkinson disease.
    Yamamoto N; Sawada H; Izumi Y; Kume T; Katsuki H; Shimohama S; Akaike A
    J Biol Chem; 2007 Feb; 282(7):4364-4372. PubMed ID: 17158454
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.